Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFKB1 | P19838 | 7/20 | 0.49 |
| ▸ | NFKB2 | Q00653 | 7/20 | 0.49 |
| ▸ | RELA | Q04206 | 7/20 | 0.49 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 3/20 | 0.35 |
| ▸ | CA2 | P00918 | 3/20 | 0.35 |
| ▸ | POLB | P06746 | 2/20 | 0.34 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.34 |
| ▸ | CA12 | O43570 | 4/20 | 0.33 |
| ▸ | CA9 | Q16790 | 4/20 | 0.33 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6439354 | 1.00 | NFKB1 (0.49) | NFKB1NFKB2RELANLRP3CA1 | |
| SCHEMBL2816076 | 1.00 | NFKB1 (0.49) | NFKB1NFKB2RELANLRP3CA1 | |
| Trifluoroethanol SCHEMBL11549440 | 0.84 | NFKB1 (0.40) | NFKB1NFKB2RELANLRP3 | |
| SCHEMBL9414132 | 0.81 | NLRP3 (0.38) | NFKB1NFKB2RELANLRP3CA1 | |
| SCHEMBL9857138 | 0.79 | NFKB1 (0.47) | NFKB1NFKB2RELANLRP3CYP19A1 | |
| SCHEMBL9856833 | 0.79 | NFKB1 (0.49) | NFKB1NFKB2RELANLRP3 | |
| SCHEMBL618190 | 0.78 | NLRP3 (0.36) | NFKB1NFKB2RELANLRP3POLB | |
| SCHEMBL9856628 | 0.77 | NFKB1 (0.44) | NFKB1NFKB2RELANLRP3 | |
| SCHEMBL9856529 | 0.77 | NLRP3 (0.48) | NFKB1NFKB2RELANLRP3CYP19A1 | |
| SCHEMBL9856316 | 0.76 | NFKB1 (0.43) | NFKB1NFKB2RELANLRP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0133251-B1 | PROCESS FOR PREPARING 4-HYDROXY-2-CYCLOPENTENONES | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1988-06-22 | — | — | EP | claimed |
| US-4132726-A | INTERMEDIATES FOR PROSTAGLANDIN COMPOUNDS | TEIJIN LIMITED (JP) | 1979-01-02 | — | — | US | claimed |
| JP-63000292-A | — | — | None | — | — | JP | disclosed |
| US-8318804-B2 | Antiviral activity of cyclopentene nitro-ester and derivatives | UNIVERSITY OF SOUTH FLORIDA (US) | 2012-11-27 | — | — | US | disclosed |
| US-8236853-B1 | Formation of cyclopentene nitro-ester and derivatives | UNIVERSITY OF SOUTH FLORIDA (US) | 2012-08-07 | — | — | US | disclosed |
| US-20100249230-A1 | ANTIVIRAL ACTIVITY OF CYCLOPENTENE NITRO-ESTER AND DERIVATIVES | UNIVERSITY OF SOUTH FLORIDA (US) | 2010-09-30 | — | — | US | disclosed |
| US-7666619-B2 | Compounds and methods for regulating bacterial growth and pathogenesis | PRINCETON UNIVERSITY (US) | 2010-02-23 | — | — | US | disclosed |
| WO-2009076397-A2 | ANTIVIRAL ACTIVITY OF CYCLOPENTENE NITRO-ESTER AND DERIVATIVES | UNIVERSITY OF SOUTH FLORIDA (US) | 2009-06-18 | — | — | WO | disclosed |
| US-20090048203-A1 | SUBSTITUTED ADENINES AND THE USES THEREOF | ASTRAZENECA AB (SE) | 2009-02-19 | — | — | US | disclosed |
| EP-1805196-A1 | SUBSTITUTED ADENINES AND THE USE THEREOF | AstraZeneca AB (SE) | 2007-07-11 | — | — | EP | disclosed |
| WO-2006040558-A1 | SUBSTITUTED ADENINES AND THE USE THEREOF | ASTRAZENECA AB (SE) | 2006-04-20 | — | — | WO | disclosed |
| WO-1989000555-A1 | PROCESS FOR MANUFACTURING SYMMETRICAL DIESTERS OF BICYCLO[3.3.0]-OCTANEDIONE DICARBOXYLIC ACID | SCHERING AKTIENGESELLSCHAFT BERLIN UND BERGKAMEN (DE) | 1989-01-26 | — | — | WO | disclosed |
| EP-0299907-A1 | Process for the preparation of diesters of symmetrical bicyclo[3.3.0]octanedionedicarboxylic acids | SCHERING AKTIENGESELLSCHAFT (DE) | 1989-01-18 | — | — | EP | disclosed |
| JP-S63292-A | PRODUCTION OF OPTICALLY ACTIVE 4-HYDROXY-2-CYCLOPENTENONE | SUMITOMO CHEM CO LTD | 1988-01-05 | — | — | JP | disclosed |
| US-4683341-A | Optical resolution of oxycyclopentenone | DAICEL CHEMICAL INDUSTRIES, LTD. (JP) | 1987-07-28 | — | — | US | disclosed |
| EP-0186133-A2 | Optical resolution of oxycyclopentenone | DAICEL CHEMICAL INDUSTRIES, LTD. (JP) | 1986-07-02 | — | — | EP | disclosed |
| US-4229592-A | 4-ALPHA-ACETOXY-2-CYCLOPENTENONE-3-CARBOXALDEHYDE | KANSAS UNIVERSITY ENDOWMENT ASSOCIATION (US) | 1980-10-21 | — | — | US | disclosed |
| US-4229592-A | 4-ALPHA-ACETOXY-2-CYCLOPENTENONE-3-CARBOXALDEHYDE | KANSAS UNIVERSITY ENDOWMENT ASSOCIATION (US) | 1980-10-21 | — | — | US | disclosed |
| US-4132726-A | INTERMEDIATES FOR PROSTAGLANDIN COMPOUNDS | TEIJIN LIMITED (JP) | 1979-01-02 | — | — | US | disclosed |
| US-4008125-A | New cyclopentene-diols and new acyl esters thereof and process for their preparation | TEIJIN LIMITED (JA) | 1977-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048203-A1 | SUBSTITUTED ADENINES AND THE USES THEREOF | HPRT1, APRT, NUDT1 | NFKB1 1696/4885NFKB2 2434/4885RELA 1945/4885 |
| US-20100249230-A1 | ANTIVIRAL ACTIVITY OF CYCLOPENTENE NITRO-ESTER AND DERIVATIVES | CYP51A1, CES2, DDT | NFKB1 2273/4885NFKB2 2059/4885RELA 1209/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.